The company maintains a conservative financial profile with a debt-to-equity ratio of 0.15 as of 2026Q1, supported by a robust $241.3M cash position.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Total Current Assets | 1.28B | 1.22B | 951.13M | 915.4M | 755.7M | 681.47M | 617.7M | 463.13M | 410.73M | 382.23M | 263.83M | 244.36M | 115.3M | 62.24M |
| Cash & Short-Term Investments | 241.29M | 186.9M | 340.13M | 289.19M | 188.03M | 254.88M | 264.83M | 189.39M | 200.89M | 214.59M | 128.75M | 148.8M | 51.54M | 13.68M |
| Cash Only | 241.29M | 186.9M | 324.4M | 167.49M | 69.86M | 59.38M | 69.67M | 72.78M | 67.85M | 50.64M | 13.24M | 19.55M | 3.29M | 4.13M |
| Short-Term Investments | 0 | 0 | 15.73M | 121.7M | 118.17M | 195.5M | 195.16M | 116.61M | 133.04M | 163.95M | 115.52M | 129.26M | 48.25M | 9.54M |
| Accounts Receivable | 183.29M | 190.02M | 167.67M | 201.77M | 203.38M | 133.94M | 114.61M | 105.9M | 81.9M | 58.01M | 43.34M | 29.44M | 20.57M | 13.15M |
| Days Sales Outstanding | 45.95 | 49.41 | 51.23 | 69.57 | 87.63 | 65.39 | 74.64 | 70.61 | 67.18 | 63.44 | 60.07 | 57.75 | 59.81 | 54.03 |
| Inventory | 438.54M | 431.55M | 406.74M | 388.02M | 334.01M | 263.5M | 219.53M | 152.99M | 115.74M | 94.9M | 73.01M | 56.76M | 33.45M | 27.07M |
| Days Inventory Outstanding | 332.84 | 341.51 | 337.7 | 376.79 | 390.84 | 353.33 | 360.55 | 318.3 | 277.19 | 297.02 | 288.14 | 333.96 | 286.15 | 318.98 |
| Other Current Assets | 412.28M | 408.22M | 36.59M | 36.42M | 30.28M | 0 | 0 | 0 | 0 | 0 | 9.5M | 1.3M | 6.61M | 5.18M |
| Total Non-Current Assets | 623.03M | 609.84M | 582.06M | 640.9M | 615.19M | 562.78M | 205.28M | 202.77M | 104.28M | 94.43M | 44.43M | 19.49M | 6.08M | 8.91M |
| Property, Plant & Equipment | 329.54M | 317M | 268.45M | 280.5M | 280.41M | 227.09M | 127.43M | 135.45M | 35.41M | 30.9M | 21.46M | 8.95M | 5.18M | 2.03M |
| Fixed Asset Turnover | 4.74x | 4.43x | 4.45x | 3.77x | 3.02x | 3.29x | 4.40x | 4.04x | 12.57x | 10.80x | 12.27x | 20.79x | 24.23x | 43.75x |
| Goodwill | 166.59M | 166.75M | 165.83M | 166.27M | 166.05M | 166.39M | 8.37M | 7.66M | 7.81M | 8.18M | 0 | 0 | 0 | 0 |
| Intangible Assets | 5.95M | 6.19M | 6.51M | 83.09M | 91.72M | 90.62M | 10.64M | 25.41M | 27.25M | 23.78M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.87M | 0 | 5K | 0 | 6M |
| Other Non-Current Assets | 120.96M | 119.9M | 141.27M | 25.88M | 12.79M | 12.98M | 8.71M | 2.95M | 875K | 1.02M | 487K | 393K | 328K | 454K |
| Total Assets | 1.9B | 1.83B | 1.53B | 1.56B | 1.37B | 1.24B | 822.98M | 665.9M | 515.01M | 476.67M | 308.25M | 263.85M | 121.38M | 71.15M |
| Asset Turnover | 0.81x | 0.77x | 0.78x | 0.68x | 0.62x | 0.60x | 0.68x | 0.82x | 0.86x | 0.70x | 0.85x | 0.71x | 1.03x | 1.25x |
| Asset Growth % | 65.36% | 19.13% | -1.49% | 13.53% | 10.18% | 51.19% | 23.59% | 29.3% | 8.04% | 54.63% | 16.83% | 117.37% | 70.61% | - |
| Total Current Liabilities | 211.73M | 183.13M | 158.34M | 151.14M | 144.93M | 123.2M | 105.93M | 91.05M | 66.06M | 51.58M | 35.8M | 28.15M | 20.82M | 15.84M |
| Accounts Payable | 43.66M | 34.74M | 31.33M | 27.16M | 26.68M | 13.42M | 14.11M | 15.11M | 8.18M | 6.76M | 4.11M | 2.57M | 2.35M | 1.31M |
| Days Payables Outstanding | 26.23 | 27.49 | 26.01 | 26.37 | 31.22 | 18 | 23.17 | 31.44 | 19.58 | 21.15 | 16.22 | 15.1 | 20.09 | 15.46 |
| Short-Term Debt | 16.53M | 16.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 6.99M | 9.16M | 0 | 0 | 0 | 0 | 0 | 344K | 526K | 1.59M | 1.09M |
| Other Current Liabilities | 151.54M | 132.16M | 112.43M | 0 | 0 | 0 | 9.81M | 1.82M | 9.3M | 8.88M | 14.39M | 10.56M | 8.03M | 7.95M |
| Current Ratio | 6.02x | 6.64x | 6.01x | 6.06x | 5.21x | 5.53x | 5.83x | 5.09x | 6.22x | 7.41x | 7.37x | 8.68x | 5.54x | 3.93x |
| Quick Ratio | 3.95x | 4.29x | 3.44x | 3.49x | 2.91x | 3.39x | 3.76x | 3.41x | 4.47x | 5.57x | 5.33x | 6.66x | 3.93x | 2.22x |
| Cash Conversion Cycle | 352.55 | 363.44 | 362.92 | 420 | 447.25 | 400.73 | 412.02 | 357.47 | 324.79 | 339.31 | 331.99 | 376.61 | 325.88 | 357.55 |
| Total Non-Current Liabilities | 212.9M | 215.78M | 223.91M | 226.22M | 227.1M | 167.13M | 79.26M | 89.24M | 26.53M | 24.68M | 5.91M | 3.18M | 112.93M | 63.37M |
| Long-Term Debt | 199.65M | 203.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6M |
| Capital Lease Obligations | 406.81M | 0 | 208.8M | 220.91M | 223.82M | 163.57M | 71.25M | 73.99M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 4.78M | 4M | 4.17M | 3.3M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 13.25M | 12.32M | 15.11M | 5.31M | 3.28M | 3.56M | 3.23M | 11.24M | 22.36M | 21.38M | 5.91M | 3.18M | 112.93M | 57.37M |
| Total Liabilities | 424.63M | 398.92M | 382.25M | 377.36M | 372.03M | 290.32M | 185.19M | 180.29M | 92.59M | 76.26M | 41.71M | 31.33M | 133.75M | 79.21M |
| Total Debt | 216.18M | 219.7M | 223.39M | 234.34M | 235.77M | 173.55M | 77.28M | 82.3M | 0 | 0 | 0 | 0 | 0 | 6M |
| Net Debt | -25.11M | 32.8M | -101.02M | 66.86M | 165.91M | 114.17M | 7.61M | 9.52M | -67.85M | -50.64M | -13.24M | -19.55M | -3.29M | 1.87M |
| Debt / Equity | 0.15x | 0.15x | 0.19x | 0.20x | 0.24x | 0.18x | 0.12x | 0.17x | - | - | - | - | - | - |
| Debt / EBITDA | 1.08x | 1.06x | 6.77x | 2.32x | 7.75x | 19.48x | - | 1.48x | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.13x | 0.16x | -3.06x | 0.66x | 5.46x | 12.82x | - | 0.17x | -12.76x | -10.24x | -13.98x | -3.30x | -0.88x | - |
| Interest Coverage | 304.65x | - | 15.72x | 46.80x | 3.23x | -4.43x | - | - | - | - | - | - | - | - |
| Total Equity | 1.47B | 1.43B | 1.15B | 1.18B | 998.86M | 953.93M | 637.79M | 485.61M | 422.42M | 400.41M | 266.55M | 232.52M | -12.37M | -8.06M |
| Equity Growth % | 80.02% | 24.04% | -2.38% | 18.03% | 4.71% | 49.57% | 31.34% | 14.96% | 5.5% | 50.22% | 14.63% | 1979.73% | -53.44% | - |
| Book Value per Share | 37.27 | 36.33 | 29.31 | 30.06 | 26.40 | 25.18 | 17.83 | 13.39 | 11.71 | 11.34 | 7.96 | 16.35 | -0.50 | -0.33 |
| Total Shareholders' Equity | 1.47B | 1.43B | 1.15B | 1.18B | 998.86M | 953.93M | 641.5M | 485.89M | 422.24M | 400.41M | 266.55M | 232.52M | -12.37M | -8.06M |
| Common Stock | 39K | 39K | 38K | 39K | 38K | 37K | 36K | 35K | 34K | 33K | 31K | 30K | 5K | 4K |
| Retained Earnings | 270.27M | 237.69M | 60M | 134.86M | 43.9M | 45.91M | 40.62M | 57.52M | 9.06M | 2M | -2.66M | -17.48M | -19.84M | -14.99M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.08M | 4.35M | -5.84M | -3.15M | -8.12M | -2.63M | 2.54M | -2.32M | -1.94M | 1.57M | -4.69M | -2.12M | -864K | 796K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | -3.71M | -279K | 175K | 0 | 0 | 0 | 0 | 0 |
Competitive VTE market saturation
According to recent balance sheet data, Penumbra has grown its total assets from $1.5B in 2024Q3 to $1.9B in 2026Q1, reflecting a consistent expansion strategy that appears to be successfully funding the company's ongoing penetration into the peripheral vascular and neurovascular procedural markets.
The steady increase in total assets suggests that the company is effectively deploying capital to scale its manufacturing and distribution infrastructure. This trajectory indicates a business model that is prioritizing market share capture over immediate balance sheet contraction, which appears sustainable given the current asset-to-liability profile.
As reported in financial statements, Penumbra maintains a conservative debt-to-equity ratio of 0.15 as of 2026Q1, signaling that the company relies minimally on external financing to fund its operations and remains well-insulated from the volatility of rising interest rates in the current macroeconomic environment.
The low leverage profile suggests that management is prioritizing financial independence, which provides a significant buffer against potential cyclical downturns in hospital capital expenditure. Investors should monitor whether this debt-averse strategy persists as the company continues to invest in higher-cost, computer-assisted aspiration systems.
Based on the provided quarterly figures, Penumbra’s current ratio of 6.02 in 2026Q1 demonstrates a substantial liquidity cushion, ensuring the company can comfortably meet its short-term obligations while maintaining the flexibility to navigate the inventory-heavy consignment model inherent in the medical device industry.
This high current ratio suggests that the company is holding significant working capital, likely in the form of inventory and accounts receivable, which is typical for a business reliant on hospital-level consignment. The liquidity position appears more than adequate to support ongoing R&D and sales force expansion without requiring additional liquidity events.
Analysis of the company's equity structure reveals that retained earnings have climbed to $270.3M in 2026Q1 from $26.0M in 2024Q3, indicating that internal profit generation is becoming a primary driver of shareholder value rather than reliance on external capital raises or dilutive equity issuance.
The consistent growth in retained earnings suggests that the company's core procedural business is generating meaningful surplus capital. This trend warrants further investigation into whether this capital will be reinvested into the 'Real System' platform or returned to shareholders, given the current lack of significant debt obligations.
Data from recent filings indicates that Penumbra's asset base includes significant investments in PPE and inventory, which, when combined with the company's consignment-heavy sales model, creates a potential risk of obsolescence as product iterations like the Thunderbolt system accelerate the lifecycle of older catheter generations.
While the balance sheet appears healthy, the reliance on consignment inventory means that a portion of reported assets may be subject to rapid devaluation if clinical preferences shift away from older product lines. Investors should monitor inventory turnover ratios to ensure that the 'shadow inventory' held at hospitals remains productive and does not lead to future write-downs.
Quick answers to the most common questions about buying PEN stock.
As of 2025, Penumbra, Inc. (PEN) had total assets of $1.83B including $1.22B in current assets.
Penumbra, Inc. (PEN) carries total debt of $219.7M, offset by $186.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Penumbra, Inc. (PEN) has total shareholders' equity (book value) of $1.43B ($36.33 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Penumbra, Inc. (PEN) reported a current ratio of 6.64x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.